Anticancer activity of novel copper(II) compound with an acylhydrazone ligand derived from thiophene against 2D and 3D human breast cancer models

BALSA, L.M.; RODRIGUEZ M.R.; PARAJON- COSTA B.; GONZALES BARO AG; LEON I.E

Congreso; VII Latin American Meeting on Biological Inorganic Chemistry (LABIC); 2021

The development of novel copper(II) complexes has shown to be very potential as anti-tumor agents, attracting increasing interest as alternatives to traditional platinum drugs1. On the other hand, Schiff bases have been broadly investigated due to their antibacterial and antitumor properties 23 .The aim of this work is to evaluate the antitumoral activity of a novel Cu(II) complex, with a hydrazone ligand derived from o-vanillin and a thiophene hydrazide [Cu(HL)] 4, in 2D (monolayer) and 3D (multicellular spheroids) cancer models. The cytotoxic activity in the 2D model was tested against a panel of human cancer cell lines including Jurkat (leukemia), MG-63 (osteosarcoma), A549 (lung), HT-29 (colorectal), MDA-MB-231 (triple negative breast) and MCF7 (hormone-dependent breast), and two normal cell line L929 (mouse fribroblast) and MCF10 (non-tumorigenic epithelial breast), using MTT assay. The complex significantly reduced the cell viability in all cell lines tested (Jurkat IC50: 2.84µM; MG-63 IC50: 1.98µM; A549 IC50: 3.07µM; HT29 IC50: 7.36µM; MDA-MB-231 IC50: 1.65µM; MCF7 IC50: 1.67µM; L929 IC50: 3.61µM; MCF10 IC50: 2.94µM) (p